No Early Relief for JW Therapeutics from Cancer Wonder Drug

The biotech company logs revenue of 66 million yuan from its cutting-edge cancer therapy, but losses jump more than 50% to nearly 430 million yuan. Key Takeaways: JW Therapeutics prices its new cancer therapy at around a million yuan, with the high production costs hard to bring down.  Large-scale market expansion is not going to be easy  The company is undervalued compared with its peers pending further progress in commercializing its products By Molly Wen A medical breakthrough is only one milestone on a long and uncertain road to mass…

Read More »

FAST NEWS: CanSino’s Inhaled Covid Booster Gets China Green Light

The latest: CanSino Biologics Inc. (6185.HK; 688185.SH) announced on Sunday that China’s National Medical Products Administration (NMPA) have given emergency use authorization for its inhaled recombinant Covid-19 vaccine for use as a booster vaccine. Looking up: CanSino says the vaccine not only stimulated humoral and cellular immunity, but also induced mucosal immunity to achieve triple comprehensive protection against Covid-19 without an injection. The inhaled vaccine also has unique advantages of painlessness and convenience. Take Note: The company said that although the vaccine was authorized for emergency use, it will still face…

Read More »

VNET Slashes Expansion Plans as Private Equity Buyout Remains in Play

The smallest of China’s three private data center operators by market value cut its 2022 plans for new cabinet installations by 30%, citing delayed customer demand Key Takeaways: VNET has slashed its plans for new cabinet installations this year by 30% and lowered its revenue outlook by a more modest 2.6% The company has hired Citigroup to advise it on a buyout offer led by Hina Group from April this year By Doug Young One has to wonder what Samuel Shen, CEO of data center operator VNET Group Inc. (VNET.US),…

Read More »